

From: [REDACTED]@eppa.com]
Sent: Tuesday, November 28, 2017 4:03 PM
To: CHAZE Nathalie (CAB-ANDRIUKAITIS)
Cc: [REDACTED] (SANTE)
Subject: Cholecalciferol (Vitamin D3): approval under the BPR & ED

Dear Mrs Chaze,

I am pleased to attach herewith a paper on the potential Paradox concerning cholecalciferol (vitamin D3) and its approval under the BPR. We are particularly concerned since the consumer market represents 50% of the total business and the latter would be lost in case a vitamin such as D3 would fall under the criteria for ED. In such a scenario, an innovative solution would not be accessible to many consumers across the EU while it is not even sure that the professional market would be sufficient to absorb the investment.

We would please to hear your views on this difficult dossier.

Kind regards,

[REDACTED] Partner
Direct +32 [REDACTED]



EPPA sa/nv
2 Place du Luxembourg | BE-1050 Brussels
tel +32 [REDACTED]
www.eppa.com | www.highlevelgroup.eu | www.reachimpact.com